[Concurrent chemoradiotherapy followed by docetaxel and cisplatin consolidation chemotherapy in elderly patients with esophageal carcinoma].
To investigate the clinical efficacy of consolidation chemotherapy with docetaxel and cisplatin (DP) in elderly patients of esophageal cancer.  Methods: Seventy-nine elderly patients of esophageal cancer were randomly divided into the treatment group (38 patients) and the control group (41 patients). Intensity modulated radiation therapy (IMRT) was applied in both groups and prescribed dose was set to 56 to 59.4 Gy in 28 to 33 fractions. The concurrent chemotherapy regime for both groups was as follow: docetaxel 25 mg/m2 plus cisplatin 25 mg/m2, per week. After concurrent chemoradiotherapy, consolidated chemotherapy was applied to the treatment group with docetaxel 60 mg/m2 and cisplatin 75 mg/m2  for 3 weeks in one cycle. There was no subsequent treatment for the control group.  Results: The clinical efficacy was assessed in 76 patients. For the treatment group, 31 patients (response rate, 89.2%) obtained effective response, including 10 cases with complete response (CR) and 21 cases with partial response (PR), both of which were significantly more than that in the control group (response rate, 61.5%), with 9 cases of CR and 15 cases of PR. The median progression-free survival was 19.7 months in the treatment group, clearly longer than that in the control group (10.8 months, P=0.04). The overall survival for 1-year, 2-year and 3-year were 78.5%, 57.9% and 37.8% in the treatment group versus 61.2%, 42.3% and 22.7% in the control group (P>0.05), respectively. Grade 1 and 2 adverse effects were commonly observed in both groups, such as hematologic toxicity and radiation-induced esophagitis, but there was no significant difference between the two groups.   Conclusion: For elderly patients with esophageal carcinoma, the overall response rate can be significantly improved by concurrent chemoradiotherapy with subsequently consolidated chemotherapy based on docetaxel and cisplatin..
Graduate School, Weifang Medical College, Weifang Shandong 261061, China.
Hui
H
Luo
Department of Oncology, School of Medicine, Shandong University,  Jinan 250011, China.
Lili
L
Qiao
Department of Radiation Oncology, Qianfoshan Hospital Affiliated to Shandong University, Jinan 250014, China.
Ning
N
Liang
Department of Radiation Oncology, Qianfoshan Hospital Affiliated to Shandong University, Jinan 250014, China.
Jian
J
Xie
Department of Radiation Oncology, Qianfoshan Hospital Affiliated to Shandong University, Jinan 250014, China.
Xinshuang
X
Yu
Department of Radiation Oncology, Qianfoshan Hospital Affiliated to Shandong University, Jinan 250014, China.
Jiandong
J
Zhang
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects; D059248:Chemoradiotherapy / Q000009:adverse effects; D002945:Cisplatin / Q000009:adverse effects; D060830:Consolidation Chemotherapy / Q000009:adverse effects; D018572:Disease-Free Survival; D000077143:Docetaxel; D004938:Esophageal Neoplasms / Q000401:mortality*; D004941:Esophagitis / Q000453:epidemiology; D005260:Female; D006402:Hematologic Diseases / Q000453:epidemiology; D006801:Humans; D008297:Male; D050397:Radiotherapy, Intensity-Modulated / Q000009:adverse effects; D012074:Remission Induction; D043823:Taxoids / Q000009:adverse effects
D043823:Taxoids; D000077143:Docetaxel; D002945:Cisplatin